{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:03:03Z","timestamp":1772258583122,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40744-023-00588-4","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T14:01:47Z","timestamp":1694872907000},"page":"1785-1794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5774-9643","authenticated-orcid":false,"given":"Silvia","family":"Scriffignano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-5205","authenticated-orcid":false,"given":"Fabio Massimo","family":"Perrotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7767-3156","authenticated-orcid":false,"given":"Paola","family":"Conigliaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1074-0861","authenticated-orcid":false,"given":"Mario","family":"Ferraioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-2825","authenticated-orcid":false,"given":"Paola","family":"Triggianese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-1729","authenticated-orcid":false,"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-5328","authenticated-orcid":false,"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,16]]},"reference":[{"key":"588_CR1","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3899\/jrheum.190054","volume":"46","author":"E Lubrano","year":"2019","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. Psoriatic arthritis, psoriatic disease, or psoriatic syndrome? J Rheumatol. 2019;46:1428\u201330.","journal-title":"J Rheumatol"},{"key":"588_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17:65\u201370.","journal-title":"Clin Med (Lond)"},{"key":"588_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40744-019-00171-w","volume":"6","author":"E Lubrano","year":"2019","unstructured":"Lubrano E, Perrotta FM, Scriffignano S, et al. Sustained very low disease activity and remission in psoriatic arthritis patients. Rheumatol Ther. 2019;6:521\u20138.","journal-title":"Rheumatol Ther"},{"key":"588_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s10067-011-1680-y","volume":"30","author":"R Scarpa","year":"2011","unstructured":"Scarpa R, Atteno M, Lubrano E, et al. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol. 2011;30:1063\u20137.","journal-title":"Clin Rheumatol"},{"key":"588_CR5","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69:1441\u20137.","journal-title":"Ann Rheum Dis"},{"key":"588_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48\u201353.","journal-title":"Ann Rheum Dis"},{"key":"588_CR7","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","volume":"72","author":"PS Helliwell","year":"2013","unstructured":"Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:986\u201391.","journal-title":"Ann Rheum Dis"},{"key":"588_CR8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/ard.2010.129379","volume":"70","author":"A Mumtaz","year":"2011","unstructured":"Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70:272\u20137.","journal-title":"Ann Rheum Dis"},{"key":"588_CR9","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.3899\/jrheum.150595","volume":"42","author":"E Lubrano","year":"2015","unstructured":"Lubrano E, Perrotta FM, Parsons WJ, et al. Patient\u2019s global assessment as an outcome measure for psoriatic arthritis in clinical practice: a surrogate for measuring low disease activity? J Rheumatol. 2015;42:2332\u20138.","journal-title":"J Rheumatol"},{"key":"588_CR10","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/1744666X.2020.1685382","volume":"15","author":"E Lubrano","year":"2019","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis. Expert Rev Clin Immunol. 2019;15:1303\u201312.","journal-title":"Expert Rev Clin Immunol"},{"key":"588_CR11","doi-asserted-by":"publisher","first-page":"e002706","DOI":"10.1136\/rmdopen-2022-002706","volume":"8","author":"SVJ Snoeck Henkemans","year":"2022","unstructured":"Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, et al. Importance of quick attainment of minimal disease activity for a positive impact on lives of patients with psoriatic arthritis. RMD Open. 2022;8:e002706.","journal-title":"RMD Open"},{"key":"588_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3899\/jrheum.170449","volume":"45","author":"L Gossec","year":"2018","unstructured":"Gossec L, McGonagle D, Korotaeva T, et al. Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature. J Rheumatol. 2018;45:6\u201313.","journal-title":"J Rheumatol"},{"key":"588_CR13","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s40744-021-00343-7","volume":"8","author":"E Lubrano","year":"2021","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. The \u201cClimb\u201d towards minimal disease activity in psoriatic arthritis. Rheumatol Ther. 2021;8:1443\u201350.","journal-title":"Rheumatol Ther"},{"key":"588_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13075-022-02838-2","volume":"24","author":"R Queiro","year":"2022","unstructured":"Queiro R, Seoane-Mato D, Laiz A, et al. Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning. Arthritis Res Ther. 2022;24:153.","journal-title":"Arthritis Res Ther"},{"key":"588_CR15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3899\/jrheum.170112","volume":"44","author":"E Lubrano","year":"2017","unstructured":"Lubrano E, De Socio A, Perrotta FM. Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: a cross-sectional analysis of a longitudinal cohort. J Rheumatol. 2017;44:1159\u201364.","journal-title":"J Rheumatol"},{"key":"588_CR16","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s10067-017-3769-4","volume":"36","author":"MS Chimenti","year":"2017","unstructured":"Chimenti MS, Triggianese P, Conigliaro P, et al. A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors. Clin Rheumatol. 2017;36:2253\u201360.","journal-title":"Clin Rheumatol"},{"key":"588_CR17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/14712598.2020.1761957","volume":"20","author":"MS Chimenti","year":"2020","unstructured":"Chimenti MS, Fonti GL, Conigliaro P, et al. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther. 2020;20:813\u201321.","journal-title":"Expert Opin Biol Ther"},{"key":"588_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3899\/jrheum.190677","volume":"47","author":"M Zardin-Moraes","year":"2020","unstructured":"Zardin-Moraes M, da Silva ALFA, Saldanha C, et al. Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis. J Rheumatol. 2020;47:839\u201346.","journal-title":"J Rheumatol"},{"key":"588_CR19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/acr.24593","volume":"74","author":"A Wong","year":"2022","unstructured":"Wong A, Ye JY, Cook RJ, et al. Depression and anxiety reduce the probability of achieving a state of sustained minimal disease activity in patients with psoriatic arthritis. Arthritis Care Res (Hoboken). 2022;74:1430\u20134.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"588_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","volume":"74","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74:813\u20137.","journal-title":"Ann Rheum Dis"},{"key":"588_CR21","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, CASPAR Study Group, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373.","journal-title":"Arthritis Rheum"},{"key":"#cr-split#-588_CR22.1","unstructured":"R version 3.6.2 (2019) Dark and Stormy Night\" Copyright"},{"key":"#cr-split#-588_CR22.2","unstructured":"(C) 2019 The R Foundation for Statistical Computing Platform: x86_64-apple-darwin15.6.0 (64-bit)."},{"key":"588_CR23","unstructured":"R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/."},{"key":"588_CR24","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3899\/jrheum.190679","volume":"47","author":"E Lubrano","year":"2020","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. Residual disease activity and associated factors in psoriatic arthritis. J Rheumatol. 2020;47:1490\u20135.","journal-title":"J Rheumatol"},{"key":"588_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40744-022-00514-0","volume":"10","author":"E Lubrano","year":"2023","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. Sequencing of biologic and target synthetic disease-modifying anti-rheumatic drugs in psoriatic arthritis: are we ready to redefine the treatment strategy? A Perspective Rheumatol Ther. 2023;10:301\u20136.","journal-title":"A Perspective Rheumatol Ther"},{"key":"588_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40744-020-00229-0","volume":"7","author":"E Lubrano","year":"2020","unstructured":"Lubrano E, Scriffignano S, Azuaga AB, et al. Impact of comorbidities on disease activity, patient global assessment, and function in psoriatic arthritis: a cross-sectional study. Rheumatol Ther. 2020;7:825\u201336.","journal-title":"Rheumatol Ther."},{"key":"588_CR27","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/1744666X.2021.1825941","volume":"16","author":"E Lubrano","year":"2020","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. Multimorbidity and comorbidity in psoriatic arthritis a perspective. Expert Rev Clin Immunol. 2020;16:963\u201372.","journal-title":"Expert Rev Clin Immunol"},{"key":"588_CR28","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40744-022-00461-w","volume":"9","author":"FM Perrotta","year":"2022","unstructured":"Perrotta FM, Scriffignano S, Ciccia F, Lubrano E. Clinical characteristics of potential \u201cdifficult-to-treat\u201d patients with psoriatic arthritis: a retrospective analysis of a longitudinal cohort. Rheumatol Ther. 2022;9:1193\u2013201.","journal-title":"Rheumatol Ther"},{"key":"588_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40744-023-00535-3","volume":"10","author":"E Lubrano","year":"2023","unstructured":"Lubrano E, Scriffignano S, Fatica M, et al. Psoriatic arthritis in males and females: differences and similarities. Rheumatol Ther. 2023;10:589\u201399.","journal-title":"Rheumatol Ther"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00588-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00588-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00588-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:38:42Z","timestamp":1700152722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00588-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,16]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["588"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00588-4","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,16]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ennio Lubrano, Silvia Scriffignano, Mauro Fatica, Paola Triggianese, Paola Conigliaro, Fabio Massimo Perrotta and Maria Sole Chimenti have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. The study was approved by the Institutional Review Board of the University of Molise (protocol n. 0001-017-2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}